Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,1700€
Last updated
23/03/2025 - 10:23
-2,63%
€10.5M
Sales in 2023
+42%
Sales growth in 2023
excluding exchange rates
+52%
PPU growth in 2023
excluding exchange rates
Events and Presentations
Financial Results
Governance
Voting Rights Information – February 2025
Corporate Presentation February 2025
Voting Rights Information – January 2025
Half-Year Liquidity Contract Statement for H2 2024 with the Brokerage Firm Gilbert Dupont
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update
News
Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis
Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers
Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 64,702,127
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
Guillaume Cuvillier
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France
• Exco Socodec, represented by Monsieur Olivier Gallezot, 51, Avenue Françoise Giroud, Parc Valmy, 21066 Dijon